What is in clinical development for Bundibugyo and Sudan virus. None of these candidates is approved for use. Tracker only; not a guide to clinical availability.
Last updated
Important
Nothing on this page is an approved medical product.
Every candidate listed here is investigational. Some are in clinical
trials; some are pre-clinical; one or two are stockpiled for
emergency-use authorisation under WHO R&D Blueprint protocols. None
can be requested or purchased as a routine clinical product. This
page exists to give journalists, public-health staff, and researchers
a current snapshot of the pipeline, not as clinical guidance.
This is editorial reference, not medical advice. If you may have been
exposed to Ebola, contact your local public-health authority.
Bundibugyo virus (BDBV) candidates
The strain behind the active 2026 PHEIC. The pipeline is thinner
than for Zaire or Sudan, partly because Bundibugyo has caused only
three recognised outbreaks before 2026.
cAd3-BDBV (BDBV-specific candidate)
Pre-clinicalvaccine
NIAID Vaccine Research Center · Targets BDBV
Mechanism. Chimpanzee adenovirus type 3 vector encoding the Bundibugyo virus glycoprotein. The platform mirrors cAd3-EBO Z (Zaire) and cAd3-EBO S (Sudan).
Status. Reported in pre-clinical animal studies. No human trials of a BDBV-specific cAd3 candidate are listed on ClinicalTrials.gov as of May 2026. Filovirus glycoprotein cross-reactivity may permit Phase 1 acceleration if WHO declares emergency-use scientific priority.
Mechanism. Monoclonal antibody products approved as Ebanga (mAb114, ansuvimab) and Inmazeb (REGN-EB3) for Zaire ebolavirus. Pre-clinical cross-reactivity work has examined activity against BDBV glycoprotein with mixed results.
Status. Neither product is approved for Bundibugyo. Cross-strain neutralisation has been observed in some in-vitro and animal studies; the regulatory and clinical path to expanded indication remains slow. Emergency-use protocols during a PHEIC could permit off-label evaluation under research authorisation.
SUDV has caused recurring outbreaks since 1976. Two distinct
candidate vaccines reached Phase 2 immunogenicity readouts before the
2022 Uganda Mubende outbreak. Both were prepared for emergency
deployment; neither reached randomised efficacy data because the
outbreak resolved before trials could enrol.
cAd3-EBO S
Phase 2vaccine
Sabin Vaccine Institute, NIAID, with academic partners · Targets SUDV
Mechanism. Chimpanzee adenovirus type 3 (cAd3) vector encoding the Sudan ebolavirus glycoprotein. Single-dose intramuscular regimen under investigation.
Status. Phase 2 immunogenicity data published. Sabin produced doses staged for emergency deployment to the 2022-2023 Uganda Mubende SUDV outbreak; the outbreak resolved before randomised efficacy data could be collected.
Mechanism. Recombinant vesicular stomatitis virus (rVSV) platform analogous to Ervebo, expressing the Sudan ebolavirus glycoprotein in place of Zaire. Single dose under investigation.
Status. In Phase 1/2 trials. Candidate is part of the WHO Solidarity Trial framework that would deploy multiple SUDV vaccine candidates head-to-head during an outbreak.
Bavarian Nordic + Janssen · Targets EBOV, SUDV, MARV
Mechanism. Modified vaccinia Ankara (MVA-BN) vector encoding glycoproteins from multiple filoviruses. Currently fielded as the Mvabea boost component of the approved Zabdeno + Mvabea Zaire vaccine, but also under study as a standalone heterologous boost or multivalent product.
Status. Multivalent filovirus candidate. Has shown immunogenicity across multiple ebolavirus species in Phase 1 and 2 studies. Not licensed as a standalone product.
Bavarian Nordic + Janssen · Targets EBOV, SUDV, MARV
Mechanism. Modified vaccinia Ankara (MVA-BN) vector encoding glycoproteins from multiple filoviruses. Currently fielded as the Mvabea boost component of the approved Zabdeno + Mvabea Zaire vaccine, but also under study as a standalone heterologous boost or multivalent product.
Status. Multivalent filovirus candidate. Has shown immunogenicity across multiple ebolavirus species in Phase 1 and 2 studies. Not licensed as a standalone product.
Mechanism. Monoclonal antibody products approved as Ebanga (mAb114, ansuvimab) and Inmazeb (REGN-EB3) for Zaire ebolavirus. Pre-clinical cross-reactivity work has examined activity against BDBV glycoprotein with mixed results.
Status. Neither product is approved for Bundibugyo. Cross-strain neutralisation has been observed in some in-vitro and animal studies; the regulatory and clinical path to expanded indication remains slow. Emergency-use protocols during a PHEIC could permit off-label evaluation under research authorisation.
Primary sources: ClinicalTrials.gov registration records, WHO R&D
Blueprint product profiles, NIAID and Sabin Vaccine Institute
disclosures, Bavarian Nordic and IAVI investor releases. We do not
consider press releases alone authoritative; where possible, the
trial registration is the canonical source.
